SCHEMBL25804653

SCHEMBL25804653

O=c1c(OCOP(O)O)c(-c2ccc(O)c(O)c2)oc2cc(O)ccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.60
KMT2A Q03164 7/20 0.60
KDM4E B2RXH2 6/20 0.60
MAPT P10636 6/20 0.60
HSD17B10 Q99714 6/20 0.60
RECQL P46063 5/20 0.60
TP53 P04637 5/20 0.60
CYP3A4 P08684 5/20 0.60
MAPK1 P28482 5/20 0.60
ALOX15 P16050 4/20 0.60
ALDH1A1 P00352 4/20 0.60
HPGD P15428 4/20 0.60
CYP2C9 P11712 4/20 0.60
CDK5 Q00535 3/20 0.60
CDK5R1 Q15078 3/20 0.60
APEX1 P27695 3/20 0.60
CASP1 P29466 3/20 0.60
CASP7 P55210 3/20 0.60
LMNA P02545 3/20 0.60
ALOX12 P18054 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25804568 0.91 ALDH1A1 (0.48) MEN1KMT2AKDM4EMAPTHSD17B10
SCHEMBL10860655 0.84 POLH (0.75) MEN1KMT2AKDM4EMAPTHSD17B10
SCHEMBL7685645 0.84 POLH (0.75) MEN1KMT2AKDM4EMAPTHSD17B10
SCHEMBL25842993 0.82 POLH (0.76) MEN1KMT2AKDM4EMAPTHSD17B10
SCHEMBL119937 0.81 MEN1 (0.61) MEN1KMT2AKDM4EMAPTHSD17B10
SCHEMBL29512814 0.80 KDM4E (0.73) MEN1KMT2AKDM4EMAPTHSD17B10
SCHEMBL34716 0.80 KDM4E (0.73) MEN1KMT2AKDM4EMAPTHSD17B10
SCHEMBL13076001 0.78 POLH (0.60) MEN1KMT2AKDM4EMAPTHSD17B10
SCHEMBL4286345 0.77 MEN1 (0.65) MEN1KMT2AKDM4EMAPTHSD17B10
SCHEMBL13056267 0.77 POLH (0.59) MEN1KMT2AKDM4EMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218617-A1 KILLING SENESCENT CELLS AND TREATING SENESCENCE-ASSOCIATED CONDITIONS USING A SRC INHIBITOR AND A FLAVONOID RESEARCH, MAYO FOUNDATION FOR MEDICAL EDUCATION AND 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218617-A1 KILLING SENESCENT CELLS AND TREATING SENESCENCE-ASSOCIATED CONDITIONS USING A SRC INHIBITOR AND A FLAVONOID TP53, SRC, LIMS1 MEN1 3250/4885KMT2A 2427/4885KDM4E 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.